A significant reduction in all-cause mortality risk was seen in men with type 2 diabetes who were taking phosphodiesterase type-5 inhibitors (PDE5is). Study findings were published in the journal Heart.
Researchers analyzed electronic health records of 5,956 men with type 2 diabetes between the years 2007 and 2015. A total of 1,359 received a PDE5i.
Over a mean follow-up time of 7.5 years, 248 (19.1%) deaths occurred in the PDE5i treated group compared to 1,170 (23.8%) in the non-treated group (P=0.0004). Those treated with a PDE5i had a 31% lower risk of all-cause mortality compared to non-users. Furthermore, lower rates of incident myocardial infarction (MI) were recorded for the PDE5i treated group than the non-treated group (incident rate ratio: 0.62, P<0.0001).
The lower mortality risk persisted after adjusting for age, estimated glomerular filtration rate, smoking status, prior cerebrovascular accident, hypertension, prior MI, systolic blood pressure, and statin, metformin, aspirin and β-blocker use.